Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors

Documenti analoghi

• Comprehensive analysis of body composition features in melanoma patients treated with tyrosine kinase inhibitors
  di: Miriam Mengoni, et al.
  Pubblicazione: (2024)
• Postoperative circulating tumor cells predict the benefits of tyrosine kinase inhibitor for hepatocellular carcinoma after transplantation
  di: De‐Zhen Guo, et al.
  Pubblicazione: (2025)
• Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors
  di: Sahithi Talasila, et al.
  Pubblicazione: (2024)
• Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
  di: Xuejin Ou, et al.
  Pubblicazione: (2024)
• Molecular basis for differential recognition of an allosteric inhibitor by receptor tyrosine kinases
  di: Jyoti Verma, et al.
  Pubblicazione: (2024)